| Name | Title | Contact Details |
|---|
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders.
Cofactor Genomics is pioneering the use of RNA to diagnose disease.
Northwest Bioanalytical is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.